Chief Strategy Officer Nathan Buchbinder is featured in this article alongside our partner Ibex. He comments on the growing impact of AI on breast cancer diagnosis and also explores why an enterprise pathology platform designed to incorporate a wide variety of applications is critical to realizing AI’s full potential.